Terran Biosciences Receives FDA Clearance for NM-101, the Industry’s First Software for the analysis of Neuromelanin-sensitive MRI
Imaging Technology
DECEMBER 20, 2023
a biotech platform company developing therapeutics and technologies for patients with neuropsychiatric illnesses, has received FDA clearance to market NM-101, a cloud-based software platform to analyze neuromelanin-sensitive MRI scans. milla1cf Wed, 12/20/2023 - 15:41 December 20, 2023 — Terran Biosciences, Inc. ,
Let's personalize your content